89bio Inc (ETNB)
7.35
-0.05
(-0.68%)
USD |
NASDAQ |
Jan 08, 16:00
7.365
+0.02
(+0.20%)
After-Hours: 20:00
89bio SG&A Expense (Quarterly): 10.50M for Sept. 30, 2024
SG&A Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
SG&A Expense (Quarterly) Benchmarks
| Madrigal Pharmaceuticals Inc | 107.58M |
| Eli Lilly and Co | 2.100B |
| Viking Therapeutics Inc | 13.77M |
| Akero Therapeutics Inc | 9.471M |
| NovaBay Pharmaceuticals Inc | 2.65M |